Results 171 to 180 of about 161,781 (188)

Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update

Journal of Medicinal Chemistry, 2018
Cyclin-dependent kinase 2 (CDK2) drives the progression of cells into the S- and M-phases of the cell cycle. CDK2 activity is largely dispensable for normal development, but it is critically associated with tumor growth in multiple cancer types. Although the role of CDK2 in tumorigenesis has been controversial, emerging evidence proposes that selective
Solomon Tadesse, Elizabeth C. Caldon, Wayne Tilley, Shudong Wang   +3 more
openaire   +4 more sources

Cyclin-dependent kinase 2 (cdk2) in the murine cdc2 kinaseTS mutant

Somatic Cell and Molecular Genetics, 1992
Kinases of the mammalian cdc2 family including cdk2 (cyclin-dependent kinase 2) are thought to be involved in both the G2/M transition and DNA replication. To investigate the role of cdc2 kinase and cdk2 in cell cycle progression, murine tsFT210 cells bearing a temperature-sensitive cdc2 mutation were used.
H, Yasuda, T, Nakata, M, Kamijo, R, Honda, M, Nakamura, J, Ninomiya-Tsuji, M, Yamashita, Y, Nagahama, Y, Ohba   +8 more
openaire   +2 more sources

3D-QSAR CoMFA Study on Oxindole Derivatives as Cyclin Dependent Kinase 1 (CDK1) and Cyclin Dependent Kinase 2 (CDK2) Inhibitors

Medicinal Chemistry, 2007
Cyclin dependent kinases have emerged as important drug targets with a multitude of therapeutic potentials for their inhibitors. With the purpose of designing new chemical entities with enhanced inhibitory potencies against cyclin dependent kinase 2 (CDK2) and cyclin dependent kinase 1 (CDK1), the 3D-QSAR CoMFA
Sanjeev Kumar, Singh, Nigus, Dessalew, Prasad V, Bharatam   +2 more
openaire   +2 more sources

3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors

European Journal of Medicinal Chemistry, 2006
Cyclin dependent kinases (CDKs) have appeared as an important drug targets over the years with diverse therapeutic potentials. With the objective of designing new chemical entities with enhanced inhibitory potencies against CDK 2 (CDK2) and CDK 4 (CDK4), the 3D-QSAR CoMFA study carried out on indenopyrazole derivatives as inhibitors of these kinases is
S K, Singh, N, Dessalew, P V, Bharatam
openaire   +2 more sources

Cyclin-dependent Kinase 2 (CDK-2) Expression in Nonmelanocytic Human Cutaneous Lesions

Applied Immunohistochemistry & Molecular Morphology, 2010
Lesions originating from different types of skin cells differ significantly with respect to their pathologic importance. The aim of this work was to examine as to what extent the differences in the origin are reflected in expression levels of CDK-2 and to investigate whether CDK-2 expression might be considered as potential marker useful for ...
Lukasz, Kuźbicki, Dariusz, Lange, Agata, Stanek-Widera, Barbara W, Chwirot   +3 more
openaire   +2 more sources

Regulation of mammalian cyclin-dependent kinase 2

1997
Publisher Summary This chapter discusses the regulation of mammalian cyclin-dependent kinase 2. Progression through the cell cycle is ultimately governed by the cyclin-dependent kinases (CDKs). In mammalian cells, Cdk2 is the member of the CDK family responsible for catalyzing the transition from G1 to S phase.
openaire   +2 more sources

Fragment-Based De Novo Design of Cyclin-Dependent Kinase 2 Inhibitors

2016
Cyclin-dependent kinases (CDKs) are core components of the cell cycle machinery that govern the transition between phases during cell cycle progression. Abnormalities in CDKs activity and regulation are common features of cancer, making CDK family members attractive targets for the development of anticancer drugs.
Sunil Kumar, Tripathi, Poonam, Singh, Sanjeev Kumar, Singh   +2 more
openaire   +2 more sources

Docking-Based Development of Purine-like Inhibitors of Cyclin-Dependent Kinase-2

Journal of Medicinal Chemistry, 2000
The cell division cycle is controlled by cyclin-dependent kinases (cdk), which consist of a catalytic subunit (cdk1-cdk8) and a regulatory subunit (cyclin A-H). Purine-like inhibitors of cyclin-dependent kinases have recently been found to be of potential use as anticancer drugs.
M, Otyepka, V, Krystof, L, Havlícek, V, Siglerová, M, Strnad, J, Koca   +5 more
openaire   +2 more sources

Cyclin-dependent kinase 2 regulates the interaction of Axin with β-catenin

Biochemical and Biophysical Research Communications, 2004
Axin, a negative regulator of Wnt, forms a complex with glycogen synthase kinase 3beta, beta-catenin, and adenomatous polyposis coli and promotes GSK3beta-dependent phosphorylation of beta-catenin, thereby stimulating degradation of the beta-catenin. An essential step in that process is the phosphorylation of Axin.
Sung Il, Kim, Chun Shik, Park, Mi Su, Lee, Min Seong, Kwon, Eek-hoon, Jho, Woo Keun, Song   +5 more
openaire   +2 more sources

Structure-assisted drug discovery: cyclin-dependent kinase 2

Acta Crystallographica Section A Foundations and Advances, 2022
S. Djukic, J. Škerlová, M. Peřina, J. Radek, V. Kryštof, P. Řezáčová   +5 more
openaire   +1 more source